Vera Bradley, the maker of quilted bags and accessories, is changing strategy again following a rebrand that de-emphasized its signature florals and patterns—and left some of its loyal consumers ...

Nvidia Introduces Vera Rubin, a New AI Supercomputing Platform Built to Slash Costs Your email has been sent Nvidia stole the CES spotlight this week with a platform designed to redefine how the world ...

A pill form of weight-loss drug Wegovy, manufactured by Danish drugmaker Novo Nordisk, is now available in the U.S., giving Americans access to an oral medication to treat obesity. The starting dose ...

The Rubin GPU boasts five times more AI training compute power than Blackwell. The Rubin GPU boasts five times more AI training compute power than Blackwell. is a news writer covering all things ...

Shortly after scoring a historic FDA nod for its Wegovy pill, Novo Nordisk is off to the races with the oral obesity med’s launch. The once-daily pill officially debuted in the U.S. Monday, with the ...

Novo Nordisk’s (NYSE: NVO) Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable 2x story moving forward, provided it effectively ...

Nvidia has unveiled its Vera Rubin compute platform with an architecture designed to power agentic artificial intelligence (AI) systems that think and reason rather than simply retrieve information.

Those who anticipated NVIDIA CEO Jensen Huang would delay delivering an update on its next big AI chip — the Vera Rubin processor first discussed last March at the company’s GTC conference in San Jose ...

Looking ahead: Nvidia kicked off the year with an unusual move: unveiling its next-generation AI computing architecture months ahead of schedule. At CES 2026 in Las Vegas, CEO Jensen Huang used his ...

American patients can now receive the first-ever GLP-1 pill for weight loss from Novo Nordisk, marking a new chapter of obesity treatment in the U.S. The cash prices for the drug, called the Wegovy ...

Eli Lilly leads the weight loss market ahead of Novo Nordisk. Eli Lilly also has a more diversified lineup of products than its peer. Even considering its seemingly more reasonable valuation, Novo ...

Novo launches Wegovy pill in competitive obesity drug market Eli Lilly expects weight-loss pill decision later this year Novo targets self-pay market with oral option over injectable Starter dose of ...